C07D 515/16
Peri-condensed systems
C07D515/16 (Peri-condensed systems) appears on 10 US grants and 13 published applications in this corpus.
Search patents in C07D- Granted patents
- 10
- Published applications
- 13
- Assignees
- 8
- Inventors
- 23
- Latest grant
- 29 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 2 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 1 | 2 |
By publication year.
Recent patents
- Diaryl macrocyclic compound and pharmaceutical composition, and use thereof29 Oct 2024US 12,129,258 B2PrimeGene (Beijing) Co., Ltd.
- Oxygen linked pyrimidine derivatives5 Oct 2021US 11,135,227 B2Cti Biopharma Corp.
- Oxygen linked pyrimidine derivatives31 Dec 2019US 10,517,876 B2Cti Biopharma Corp.
- Oxygen linked pyrimidine derivatives21 Feb 2017US 9,573,964 B2Cti Biopharma Corp.
- Macrocyclic LRRK2 kinase inhibitors21 Jun 2016US 9,370,520 B2Ipsen Pharma S.A.S.
- Sarm1 enzyme activity inhibitor and application thereof7 Nov 2024US 2024/0368168 A1Artivila Biopharma
- Macrocyclic compound, pharmaceutical composition, and use thereof25 Apr 2024US 2024/0132517 A1Goharmony Therapeutics (Shenzhen) Co., Ltd.
- Oxygen linked pyrimidine derivatives4 Aug 2022US 2022/0241291 A1Cti Biopharma Corp.
- Diaryl macrocyclic compound and pharmaceutical composition, and use thereof26 May 2022US 2022/0162218 A1PrimeGene (Beijing) Co., Ltd.
- Oxygen linked pyrimidine derivatives5 Mar 2020US 2020/0071339 A1Cti Biopharma Corp.
Most cited
By later US patents
- Heteroalkyl linked pyrimidine derivatives6US 8,143,255 B2S'bio Pte Ltd · 2012
- Heteroalkyl linked pyrimidine derivatives6US 9,133,214 B2S'bio Pte Ltd · 2015
- Oxygen linked pyrimidine derivatives5US 8,415,338 B2Cell Therapeutics, Inc. · 2013
- Macrocyclic LRRK2 kinase inhibitors5US 9,096,609 B2Ipsen Pharma S.A.S. · 2015
- Macrocyclic LRRK2 kinase inhibitors4US 9,370,520 B2Ipsen Pharma S.A.S. · 2016